Release of levetiracetam from extended-release tablets that appear intact in patient stool

被引：1
|
作者：
Vaithianathan, Soundarya [1 ]
Ting, Tricia Y. [2 ]
Jiang, Wenlei [3 ]
Polli, James E. [1 ]
机构：
[1] Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
[2] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA
[3] US FDA, White Oak, MD USA
来源：
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | 2016年 / 40卷
关键词：
Levetiracetam; Extended-release; Generic; Stool; Tablet Remnant;
D O I：
10.1016/j.seizure.2016.05.011
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：7 / 9
页数：3
相关论文
共 50 条
  • [31] Liquid Chromatographic Determination of Norfloxacin in Extended-Release Tablets
    Oliveira, Paulo R.
    Bernardi, Larissa S.
    Mendes, Cassiana
    Cardoso, Simone G.
    Sangoi, Maximiliano S.
    Silva, Marcos A. S.
    JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2009, 47 (09) : 739 - 744
  • [32] A summary of the pharmacokinetic characteristics of lamotrigine extended-release tablets
    Kustra, Robert
    Tompson, D.
    Job, S.
    VanLandingham, K.
    EPILEPSIA, 2007, 48 : 373 - 373
  • [33] Preparation and scale up of extended-release tablets of bromopride
    Ferreira, Guilherme Neves
    Rodrigues Silva, Marcos Giovani
    Manssour Fraga, Aline Guerra
    Rodrigues Pereira da Silva, Luiz Claudio
    Lira, Luiz Marcelo
    Rodrigues, Carlos Rangel
    Castro, Helena Carla
    de Sousa, Valeria Pereira
    Cabral, Lucio Mendes
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 50 (02) : 291 - 300
  • [34] Converting from incoming opioids to oxycodone extended-release (OXYCR) tablets or oxycodone/naloxone extended-release (OXN) tablets - an analysis of the experience from 5 controlled clinical trials
    Steiner, D.
    Moline, M.
    Munera, C.
    Berger, B.
    JOURNAL OF PAIN, 2014, 15 (04): : S89 - S89
  • [35] A Case of Opioid Toxicity on Conversion From Extended-Release Oxycodone and Naloxone to Extended-Release Oxycodone in a Patient With Liver Dysfunction
    Franklin, Abigail E.
    Lovell, Melanie R.
    Boyle, Frances
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2017, 53 (02) : E1 - E2
  • [36] A Comparison of the Pharmacokinetics of Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults
    Childress, Ann
    Stark, Jeffrey G.
    McMahen, Russ
    Engelking, Dorothy
    Sikes, Carolyn
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (02): : 151 - 159
  • [37] DOSE-PROPORTIONALITY OF LEVETIRACETAM 500 MG EXTENDED-RELEASE TABLETS FROM 1 G TO 3 G ONCE DAILY
    Troenaru, Mona
    Toublanc, N.
    Burton, I.
    Gelu-Mantoulet, S.
    Valgaeren, A.
    Otoul, Christian
    Sargentini-Maier, Maria Laura
    Stockis, Armel
    EPILEPSIA, 2008, 49 : 459 - 460
  • [38] MEASUREMENT OF DRUG RELEASE FROM EXTENDED-RELEASE PRODUCTS
    MANNI, PE
    PHARMACOPEIAL FORUM, 1981, 7 (02): : 863 - 863
  • [39] Polysaccharides as potential antioxidative compounds for extended-release matrix tablets
    Tomida, Hisao
    Yasufuku, Taira
    Fujii, Takeshi
    Kondo, Yuko
    Kai, Toshiya
    Anraku, Makoto
    CARBOHYDRATE RESEARCH, 2010, 345 (01) : 82 - 86
  • [40] Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia
    Fowler, Jill A.
    Bettinger, Tawny L.
    Argo, Tami R.
    CLINICAL THERAPEUTICS, 2008, 30 (02) : 231 - 248
12345